LitCovid-sentences  

PMC:7352545 / 72762-74228 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T707 0-79 Sentence denotes CLQ and CLQ-OH are under investigation worldwide to treat COVID-19 (Figure 10).
T708 80-224 Sentence denotes CLQ and its derivative CLQ-OH block CoV replication, amplification and spread in in vitro culture via inhibition of ACE2 receptor glycosylation.
T709 225-369 Sentence denotes In HCoVs, interaction of the S glycoprotein with gangliosides initially occur as the first entry step during the replication cycle of the virus.
T710 370-515 Sentence denotes CLQ and CLQ-OH have been alternative drugs for RA and several autoimmune diseases for 70 years, although they are anti-malaria prophylaxis drugs.
T711 516-572 Sentence denotes CLQ-OH is an aminoquinoline with less toxicity than CLQ.
T712 573-669 Sentence denotes CLQ-OH bears an N-hydroxyethyl side chain, which increases its solubility compared to CLQ [141].
T713 670-772 Sentence denotes CLQ-OH modulates activated immune cells via downregulation of TLR signaling and IL-6 production [142].
T714 773-861 Sentence denotes Clinical trials are also under consideration for the efficacy and safety of these drugs.
T715 862-978 Sentence denotes Regarding the action mechanism(s), CLQ and CLQ-OH-mediated inhibition of ACE2 terminal glycosylation was considered.
T716 979-1165 Sentence denotes In in vitro Vero E6 cells, CLQ significantly inhibits SARS-CoV spread by interfering with ACE2 function, acting at the entry and post-entry steps of SARS-CoV-2 replication and infection.
T717 1166-1272 Sentence denotes The binding affinity of ACE2 to S glycoprotein is simulated to be lowered by treatment with CLQ-OH or CLQ.
T718 1273-1394 Sentence denotes CLQ may modify the binding affinity between ACE2 and S glycoprotein by alterations in ACE2 glycosylation or modification.
T719 1395-1466 Sentence denotes CLQ-OH (EC50 0.72 μM) and CLQ (EC50, 5.47 μM) inhibit SARS-CoV-2 [143].